OS Therapies (OSTX) said Tuesday it closed the $6 million private placement financing of 1.5 million units.
Each unit in the offering includes one share of series A senior convertible preferred stock and one warrant to purchase one common share, according to the company.
The units were priced at $4 apiece with a $4 conversion price of preferred stock into one common share and a $4.40 per share exercise price of the warrants, OS Therapies added.
The company said proceeds from the private placement will be used for working capital and general capital purposes.
OS Therapies expects the capital raised to sustain operations into 2026 and anticipates delivering clinical data and biologics license application requirements needed to obtain US Food and Drug Administration authorization for the commercialization of OST-HER2 to prevent recurrent, resected metastatic osteosarcoma in the US.
Shares of OS Therapies were down more than 10% in recent trading.
Price: 4.22, Change: -0.48, Percent Change: -10.15
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。